{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:11:37Z","timestamp":1793412697692,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T00:00:00Z","timestamp":1588032000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T00:00:00Z","timestamp":1588032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background\/purpose<\/jats:title>\n<jats:p>Studies have demonstrated that rheumatoid arthritis (RA) patients who achieve low disease activity or remission are able to taper biological disease-modifying antirheumatic drugs (bDMARDs). The aim of this study was to evaluate the proportion of patients in whom bDMARDs can be tapered in daily practice and to analyse the characteristics of these patients. Other objectives were to analyse which bDMARDs are more suitable for dose reduction and the cost savings.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Data from 332 eligible RA patients from our Brussels UCLouvain cohort were retrospectively analysed; 140 patients (42.1%) received a tapered regimen, and 192 received stable doses of bDMARDs. The age at diagnosis (43.1 vs 38.7 years, <jats:italic>p<\/jats:italic>\u2009=\u20090.04), health assessment questionnaire (HAQ) score (1.3 vs 1.5, <jats:italic>p<\/jats:italic>\u2009=\u20090.048), RF positivity rate (83.3 vs 72.9%, <jats:italic>p<\/jats:italic>\u2009=\u20090.04) and disease duration at the time of bDMARD introduction (9.7 vs 12.1\u2009years, <jats:italic>p<\/jats:italic>\u2009=\u20090.034) were significantly different between the reduced-dose and stable-dose groups. Interestingly, relatively more patients receiving a tapered dose were treated with a combination of bDMARDs and methotrexate (MTX) (86.7% vs 73.8%, <jats:italic>p<\/jats:italic>\u2009=\u20090.005). In our cohort, anti-TNF agents were the most commonly prescribed medications (68%). Only 15 patients experienced a flare during follow-up. Adalimumab, etanercept and rituximab were the most common bDMARDs in the reduced-dose group and were associated with the most important reductions in annual cost.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>In daily practice, tapering bDMARDs in RA patients who have achieved low disease activity or remission is an achievable goal in a large proportion of patients, thereby reducing potential side effects and annual drug-associated costs. The combination of bDMARDs with MTX could improve the success of dose reduction attempts.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>This retrospective non-interventional study was retrospectively registered with local ethics approval.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13075-020-02165-4","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T18:04:26Z","timestamp":1588097066000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort"],"prefix":"10.1186","volume":"22","author":[{"given":"St\u00e9phanie","family":"Dierckx","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Sokolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard R.","family":"Lauwerys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Avramovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent Meric","family":"de Bellefon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien Nzeusseu","family":"Toukap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Stoenoiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric A.","family":"Houssiau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Durez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,28]]},"reference":[{"key":"2165_CR1","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960\u201377.","journal-title":"Ann Rheum Dis"},{"key":"2165_CR2","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1136\/annrheumdis-2016-210713","volume":"76","author":"JL Nam","year":"2017","unstructured":"Nam JL, Takase-Minegishi K, Ramiro S, et al. Efficacy of biological disease modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2017;76:1113\u201336.","journal-title":"Ann Rheum Dis"},{"key":"2165_CR3","first-page":"1","volume":"2015","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Si BJ, et al. American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;2015:1\u201326.","journal-title":"Arthritis Rheumatol"},{"key":"2165_CR4","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s00296-017-3780-8","volume":"37","author":"CS Lau","year":"2017","unstructured":"Lau CS, Gibofsky A, Damjanov N, et al. Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review. Rheumatology Int. 2017;37:1789\u201398.","journal-title":"Rheumatology Int"},{"key":"2165_CR5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1136\/annrheumdis-2017-212423","volume":"77","author":"S Henaux","year":"2018","unstructured":"Henaux S, Ruyssen-Witrand A, Cantagrel A, et al. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis. Ann Rheum Dis. 2018;77:515\u201322.","journal-title":"Ann Rheum Dis"},{"key":"2165_CR6","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1093\/rheumatology\/kew464","volume":"56","author":"CJ Edwards","year":"2017","unstructured":"Edwards CJ, Fautrel B, Schulze-Koops H, et al. Dosing down with biological therapies: a systematic review and clinician\u2019s perspective. Rheumatology. 2017;56:1847\u201356.","journal-title":"Rheumatology"},{"key":"2165_CR7","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S0140-6736(12)61811-X","volume":"381","author":"JS Smolen","year":"2013","unstructured":"Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet. 2013;381:918\u201329.","journal-title":"Lancet"},{"key":"2165_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1136\/annrheumdis-2014-205726","volume":"75","author":"RF van Vollenhoven","year":"2016","unstructured":"van Vollenhoven RF, \u00d8stergaard M, Leirisalo-Repo M, et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis. 2016;75:52\u20138.","journal-title":"Ann Rheum Dis"},{"key":"2165_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/annrheumdis-2014-206696","volume":"75","author":"B Fautrel","year":"2016","unstructured":"Fautrel B, Pham T, Alfaiate T, et al. Step-down strategy of spacing TNF blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Ann Rheum Dis. 2016;75:59\u201367.","journal-title":"Ann Rheum Dis"},{"key":"2165_CR10","doi-asserted-by":"publisher","first-page":"e000474","DOI":"10.1136\/rmdopen-2017-000474","volume":"3","author":"J Sigaux","year":"2017","unstructured":"Sigaux J, Bailly F, Hajage D, et al. Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNFblocker injections in Rheumatoid ArthritiS Study) randomized controlled trial. RMD Open. 2017;3:e000474.","journal-title":"RMD Open"},{"key":"2165_CR11","doi-asserted-by":"publisher","first-page":"h1389","DOI":"10.1136\/bmj.h1389","volume":"350","author":"N van Herwaarden","year":"2015","unstructured":"van Herwaarden N, van der Maas A, Minten MJ, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ. 2015;350:h1389.","journal-title":"BMJ"},{"key":"2165_CR12","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1136\/annrheumdis-2017-211169","volume":"76","author":"CA Bouman","year":"2017","unstructured":"Bouman CA, van Herwaarden N, van den Hoogen FH, et al. Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial. Ann Rheum Dis. 2017;76:1716\u201322.","journal-title":"Ann Rheum Dis"},{"key":"2165_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/annrheumdis-2014-206439","volume":"75","author":"J Haschka","year":"2016","unstructured":"Haschka J, Englbrecht M, Hueber AJ, et al. Relapses rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomized controlled RETRO study. Ann Rheum Dis. 2016;75:45\u201351.","journal-title":"Ann Rheum Dis"},{"key":"2165_CR14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/rheumatology\/key244","volume":"58","author":"CH Brahe","year":"2019","unstructured":"Brahe CH, Krabbe S, Ostergaard M, et al. Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care - 2-year outcomes and predictors. Rheumatology. 2019;58:110\u20139.","journal-title":"Rheumatology"},{"key":"2165_CR15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0140-6736(13)61751-1","volume":"383","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet. 2014;383:321\u201332.","journal-title":"Lancet"},{"key":"2165_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1136\/annrheumdis-2018-213271","volume":"78","author":"T Takeuchi","year":"2019","unstructured":"Takeuchi T, Genovese MC, Haraoui B, et al. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Ann Rheum Dis. 2019;78:171\u20138.","journal-title":"Ann Rheum Dis"},{"key":"2165_CR17","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrrheum.2015.8","volume":"11","author":"J Smolen","year":"2015","unstructured":"Smolen J, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol. 2015;11:276\u201389.","journal-title":"Nat Rev Rheumatol"},{"key":"2165_CR18","doi-asserted-by":"publisher","first-page":"e9930","DOI":"10.1097\/MD.0000000000009930","volume":"97","author":"B Armagan","year":"2018","unstructured":"Armagan B, Sari A, Erden A, et al. Starting of biological disease modifying antirheumatic drugs may be postponed in rheumatoid arthritis patients with multimorbidity : single center real life results. Medicine. 2018;97:e9930.","journal-title":"Medicine"},{"key":"2165_CR19","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/rheumatology\/kev019","volume":"54","author":"C Gabay","year":"2015","unstructured":"Gabay C, Riek M, Scherer A, et al. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry. Rheumatology. 2015;54:1664\u201372.","journal-title":"Rheumatology"},{"key":"2165_CR20","doi-asserted-by":"publisher","first-page":"e000900","DOI":"10.1136\/rmdopen-2019-000900","volume":"5","author":"J Smolen","year":"2019","unstructured":"Smolen J, Goncalves J, Quinn M, et al. Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open. 2019;5:e000900.","journal-title":"RMD Open"},{"key":"2165_CR21","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1136\/annrheumdis-2015-208317","volume":"75","author":"W Kievit","year":"2016","unstructured":"Kievit W, van Herwaarden N, van den Hoogen FH, et al. Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Ann Rheum Dis. 2016;75:1939\u201344.","journal-title":"Ann Rheum Dis"},{"key":"2165_CR22","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1136\/annrheumdis-2011-200945","volume":"71","author":"A van der Maas","year":"2012","unstructured":"van der Maas A, Kievit W, van den Bemt BJ, et al. Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis. 2012;71:1849\u201354.","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02165-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-020-02165-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02165-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:13:04Z","timestamp":1619568784000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-02165-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,28]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2165"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-02165-4","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,28]]},"assertion":[{"value":"17 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective non-interventional study was retrospectively registered with local ethics approval. No additional consent form needed for this retrospective non-interventional SOC study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"An institutional consent form was used for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}